Who checked the peptide? HHS opens a door FDA's scientists wanted shut

5 min read

Share

A felt vial with a stopper.

A policy about access is also a policy about who answers for the vial.

On Oct. 28, the Department of Health and Human Services filed a policy saying it will not take enforcement action against licensed pharmacies and physicians that compound six popular "wellness" peptides, including BPC-157 and TB-500 [1][2]. The Associated Press reported that FDA scientists objected and would not support a regulation deeming the peptides safe [1].

The short answer: None of these six peptides is an FDA-approved drug, and none is on the list of ingredients compounders may normally use. HHS chose not to enforce the rules against compounding them while FDA writes a regulation [2]. FDA's own reviewers had proposed that every one of the six stay off that list [4]. If you are considering one, the question that matters is not whether you can buy it. It is who checked what is in it, and who is watching how you do on it.

What the news says

  • What HHS did. HHS announced a draft "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances." It says HHS "does not intend to take enforcement action" against a state-licensed pharmacy, federal facility, or licensed physician compounding a drug from a peptide on its list, while the list of allowed compounding ingredients "is developed through rulemaking" [2]. The notice publishes in the Federal Register on Oct. 30, with comments open for two weeks [2].
  • Which peptides. BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon, each with set routes, such as injection under the skin or into muscle, by mouth, on the skin, or as a nasal spray [3].
  • HHS's reason. HHS says there is "significant interest" in these peptides "given the lack of availability of approved products," and that the policy is meant "to expand and improve patient access" [2]. The AP reports HHS described it as "a more controlled alternative" to black-market peptides [1].
  • The guardrails. AJMC reports the policy sets ten conditions, including ingredients from an FDA-registered manufacturer, a certificate of analysis for purity and contaminants, one peptide per product, a patient-specific prescription, and reporting serious side effects to FDA [3].
  • The objection. The AP reports that FDA scientists had major safety concerns and warned the policy could undermine the agency's job of keeping unsafe products off the market [1].

Two FDA records, one panel vote

Here is what FDA's own documents said about the same six peptides before this week.

  • April 2026. FDA's page on bulk drug substances that "may present significant safety risks" names all six, on its list of substances previously in its safety-risk category whose nominators withdrew them [5]. For BPC-157, FDA says it found little or no safety information for the proposed routes and cannot determine whether it would cause harm in humans. For TB-500, FDA says it "has not identified any human exposure data" [5]. FDA also lists risks from impurities and immune reactions for both [5].
  • July 2026 briefing. For the advisory committee meeting on July 23 and 24, FDA wrote that it "is proposing" that each of the six, in both forms, "NOT be included on the 503A Bulks List" [4]. That is 12 of 12 [4].
  • July 2026 vote. The outside committee recommended adding all six [7]. For BPC-157, KPV, and TB-500 the vote was 8 to 6, with one abstention [6][7]. That is 57.1% of the members who voted yes or no. Committee votes are advice; FDA is not bound by them [6].

So the record has three parts: FDA's reviewers said no, a narrow panel said yes, and HHS acted before FDA finished writing a rule.

What the news does and does not show

It shows a change in enforcement, not an approval. HHS says the policy "does not establish any rights for any person and is not binding on HHS or the public," and that it may revisit the policy if "a safety signal or product quality issue arises" [2]. The peptides remain unapproved, and compounded drugs, HHS's own notice says, are not reviewed by FDA for "safety, effectiveness, or quality before they are marketed" [2].

It does not show that these peptides work or that they are unsafe. The AP reports Wall Street analysts estimate the market could top $2 billion, and HHS frames the policy as moving buyers away from unregulated sellers [1]. Both can be true: a pharmacy-made vial may be cleaner than a research-chemical vial, and still have little human data behind it.

It does not settle long-term outcomes. FDA's reviews describe how little human data exists, especially for TB-500 [5]. A policy cannot create that evidence. Only careful use, with someone tracking how patients do, can.

What you can do

  • Ask who made it. A compounded product under this policy should come from a state-licensed pharmacy, made from an ingredient from an FDA-registered manufacturer, on a prescription written for you [3]. A "research use only" label is not that.
  • Ask what is known in people. Ask your clinician what human evidence exists for your use, and what is still unknown.
  • Tell your clinicians. Let every doctor and pharmacist who treats you know if you take a peptide, so they can watch for side effects and interactions.
  • Report problems. Serious side effects can be reported to FDA's MedWatch program [8].
  • Talk with your clinician or pharmacist before you start, stop, or combine anything.

Where Temi fits

At Temi, a licensed physician reviews every request, including any compounded medication, before anything is prescribed. A refill review costs $15, or $0 with Temi Care ($449 a year); a new prescription review costs $79, or $0 with Temi Care. Temi never bills insurance. The fee pays for the review, not for a prescription, so the answer can be no.

Sources

  1. Matthew Perrone, "RFK Jr. eases access to unproven peptides despite opposition from FDA scientists," Associated Press, via Medical Xpress, Oct. 29, 2026. https://medicalxpress.com/news/2026-10-rfk-jr-eases-access-unproven.html
  2. Department of Health and Human Services, "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances," notice of availability, Docket No. HHS-OASH-2026-0496, FR Doc. 2026-22192, filed Oct. 28, 2026, publication date Oct. 30, 2026. https://www.federalregister.gov/public-inspection/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
  3. Giuliana Grossi, "HHS Draft Policy Eases Enforcement on 6 Compounded Peptides," AJMC, Oct. 29, 2026. https://www.ajmc.com/view/hhs-draft-policy-eases-enforcement-on-6-compounded-peptides
  4. U.S. Food and Drug Administration, "FDA Briefing Document, Pharmacy Compounding Advisory Committee (PCAC) Meeting, July 23-24, 2026." https://www.fda.gov/media/193342/download
  5. U.S. Food and Drug Administration, "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks," content current as of April 22, 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  6. Nicholas Jacobus, "FDA Panel Votes to Loosen Restrictions for Four Peptides," Pharmaceutical Executive, July 24, 2026. https://www.pharmexec.com/view/fda-votes-loosen-restrictions-four-peptides
  7. Raymond Miller and Christopher Mikson, "Compounding at the crossroads: FDA AdComm recommends adding six peptides to the 503A Bulk Drug Substances List," DLA Piper, July 31, 2026. https://www.dlapiper.com/en/insights/publications/2026/07/fda-adcomm-recommends-adding-six-peptides-to-bulk-list
  8. U.S. Food and Drug Administration, "MedWatch: The FDA Safety Information and Adverse Event Reporting Program." https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program

Editorial Standards

This article has not been reviewed by a licensed physician. We cite peer-reviewed studies, academic research institutions, and medical associations. Our sources are listed at the end of each article.

If you notice an error or have a concern about our content, please email supportusetemi.com.

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and treatment.

Felt Temigami re-enacting famous revolutions, from crossing the Delaware to raising a pill-bottle flag.

The revolution will be emailed.

Once a week, roughly. We're taking the fight to a corrupt and broken health insurance system. Join up.

Get Temi's newsletter by email. Unsubscribe anytime. Privacy policy

Temi

Start online, and a licensed physician reviews your request

See if you qualify

A licensed physician reviews every request. Nothing on this page is a prescription.